首页> 外文期刊>Canadian Journal of Emergency Medicine >Sepsis update: management of severe sepsis and septic shock in the emergency department after the withdrawal of Xigris
【24h】

Sepsis update: management of severe sepsis and septic shock in the emergency department after the withdrawal of Xigris

机译:败血症更新:撤回Xigris后,急诊部门应对严重的败血症和脓毒性休克进行管理

获取原文
       

摘要

Xigris, a systemic anticoagulant used for the management of patients with severe sepsis and septic shock,has recently been removed from the market. Alsoknown as drotrecogin alfa (activated) or activatedprotein C, this medication is no longer available foruse. Recommendations and guidelines (including theCanadian Association of Emergency Physicians[CAEP] sepsis guidelines1) require revision to reflectthis important development.
机译:Xigris是一种用于治疗严重脓毒症和败血性休克的全身性抗凝剂,最近已从市场上退出。也被称为drotrecogin alfa(活化的)或活化的C蛋白,这种药物不再可用。建议和指南(包括加拿大急诊医师协会[CAEP]败血症指南1)需要修订,以反映这一重要进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号